Abstract
The bentiromide test has been proposed as a useful noninvasive method for assessing exocrine pancreatic function in cystic fibrosis (CF) patients. Following oral administration, this peptide is selectively cleaved by pancreatic chymotrypsin liberating PABA which is passively absorbed. Recent studies have suggested that PABA measured in plasma is superior to the more established method of estimating urinary recovery of this marker. However, in using the plasma test in CF patients, one makes the assumption that the PABA marker has similar distribution and elimination patterns in normal and CF subjects. Since many drugs display altered pharmacokinetics in CF patients, we studied the disposition of PABA following ingestion of free PABA in six controls (age 19–28 years) and 18 CF patients (13–18 years; seven steatorrheic and 11 nonsteatorrheic). Elimination ofT1/2 of PABA was significantly shorter in CF patients (58±21 min) compared to controls (93.5±28) (P<0.005). PABA clearance was similar in the control and CF patients (2.99±1.21 and 3.27±1.02 ml/min/kg, respectively). PABA distribution volume was smaller, although not significantly so, than in the controls (268±107 vs 376±140 ml/kg). Good correlation was found between PABA distribution volume andT1/2 (r=0.51P<0.02). Our simulation data suggest that altered pharmacokinetics of PABA in CF patients would cause their PABA levels to be 7% lower than controls at 90 min, 18% at 120 min, 29% at 150 min, and 38% at 180 min. In an extreme CF case with a shortT1/2 and small distribution volume, PABA levels at 90 min would be 31% lower than that of control. At 180 min, concentrations would be lower by 72%. Our data suggest that a CF patient may have lower levels of PABA than control even in the presence of appropriate pancreatic enzyme activity. These studies indicate that early measurement of plasma PABA (90 min) would minimize this potential error.
Similar content being viewed by others
References
Arvanitakis C, Greenberger NJ: Diagnosis of pancreatic disease by a synthetic peptide. Lancet 1:663–666, 1976
Gyr K, Stadler GA, Schiffman I, et al: Oral administration of a chymotrypsin-labile peptide—a new test of exocrine pancreatic function in man. Gut 17:27–32, 1976
Delchier JC, Soule JC: BT-PABA test with plasma PABA measurements: Evaluation of sensitivity and specificity. Gut 24:318–325, 1983
Arvanitakis SN, Arvanitakis C, Desani N, Greenberger NJ: Diagnosis of exocrine pancreatic insufficiency in cystic fibrosis by the synthetic peptide BT-PABA. J Pediatr 92:734–737, 1978
Dockter G, Nacu T, Kohlberger E: Determination of protease-cleaved PABA in serum after oral administration of BT-PABA in children. Eur J Pediatr 135:277–279, 1981
Weizman Z, Forstner GG, Gaskin KJ, Kopelman H, Wong S, Durie PR: The bentiromide test for assessing pancreatic dysfunction using analysis of PABA in plasma and urine: Studies in cystic fibrosis and Shwachman syndrome. Gastroenterology (In Press)
Isles A, Spino M, Tabachnik E, Levison H, Thiessen J, MacLeod S: Theophylline disposition in cystic fibrosis. Am Rev Respir Dis 127:417–421, 1983
Arvidsson A, Alvan G, Strandvik B: Differences in renal handling of cefsulodin between patients with cystic fibrosis and normal subjects. Acta Pediatr Scand 72:293–294, 1983
Kearns GL, Hilman BC: Dosing implications of altered gentamycin disposition in patients with cystic fibrosis. J Pediatr 100:312–318, 1982
Van der Kamer HH, Huinick H, Weyers HA: Rapid method for determination of fat in feces. J Biol Chem 177:347, 1949
Toskes PP: Bentiromide as a test of exocrine pancreatic function in adult patients with pancreatic exocrine insufficiency: Determination of appropriate dose and urinary collection interval. Gastroenterology 85:565–569, 1983
Smith HW, Finkelstein N, Aluminosa L, et al: Renal clearance of hippuric acid derivatives and other aromatic acids in dog and man. J Clin Invest 24:388, 1945
Bratton AC, Marshall EK: A new coupling component for sulfamilamide determination. J Biol Chem 128:537, 1939
Metzler CM: A user's manual for NONLIN. The Upjohn Company Technical Report 7292/69/7293/005, Kalamazoo, Michigan, 1969
Gibaldi M, Perrier D: Pharmacokinetics. New York, Marcel Dekker, 1982
Sellers EM, Holloway MR: Drug kinetics and alcohol ingestion.In Handbook of Clinical Pharmacokinetics, Section 2. M Gibaldi, L Prescott (eds). Adis Health Science Press, 1983, pp. 207–281.
Author information
Authors and Affiliations
Additional information
This study was funded by a grant from the Canadian Cystic Fibrosis Foundation.
Rights and permissions
About this article
Cite this article
Koren, G., Weizman, Z., Forstner, G. et al. Altered PABA pharmacokinetics in cystic fibrosis. Digest Dis Sci 30, 928–932 (1985). https://doi.org/10.1007/BF01308291
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01308291